Asset Allocation & Fund Positioning, Copley Fund Research

Steven Holden

Steven Holden is the CEO and Founder of Copley Fund Research, an independent provider of research on equity fund positioning and performance.  Set up in 2014, Copley focuses on global, global emerging market, US, Asia Ex-Japan and China active equity funds, covering over $4tr in assets across 1300 active managers.  The company provides data and analysis on market trends, manager exposures and active fund performance to an audience of investment managers, pension funds and fund selectors worldwide.  Mr Holden’s 14-year investment banking career started in 2000, where he worked for Morgan Stanley as an equity derivative trader focused on emerging markets in London.  Following this, he spent 4 years at Citibank in London and Hong Kong as an Executive Director in derivative sales, focused again on emerging markets.

Asset Allocation & Fund Positioning

Copley Fund Research

Copley Fund Research provide research and data on asset allocation among Global and Emerging Market equity funds.  The analysis details absolute and relative positioning across countries, sectors and industries together with highly granular data on single stock and single fund allocations.  The data is updated monthly with time series going back to January 2011.

Global Research - Analysis of 165 prominent Global equity funds, combined AUM $335bn
GEM Research - Analysis of 127 prominent global EM equity funds, combined AUM $250bn

Asset Allocation - Global and GEM Equity

Cross Asset Strategy

<ul>
<li>China A-Share allocations have hit new highs every month so far this year, overtaking Russia as the 6th largest 'country' holding.</li>
<li>Sector allocations are led by Consumers, however Health Care/Industrials/Tech are seeing inflows.</li>
<li>Stock ownership is broadening out, with confidence growing outside of the well-known large cap stocks. </li>
<li>
<a href="https://www.smartkarma.com/entities/shenzhen-mindray-bio-medic-a" target="_blank" data-smartkarma-citation="entities:28017:1" rel="noopener">Shenzhen Mindray Bio-Medical Electronics (300760 CH)</a> ,  <a href="https://www.smartkarma.com/entities/xian-longi-silicon-materials-co-ltd" target="_blank" data-smartkarma-citation="entities:12703:1" rel="noopener">Xian Longi Silicon Materials (601012 CH)</a>  and <a href="https://www.smartkarma.com/entities/lepu-medical-technology-a" target="_blank" data-smartkarma-citation="entities:16654:1" rel="noopener">Lepu Medical Technology A (300003 CH)</a> are seeing investment levels rise among EM investors.</li>
</ul>


China A-Share allocations have hit new highs every month so far this year, overtaking Russia as the 6th largest 'country' holding.
Sector allocations are led by Consumers, however Health Care/Industrials/Tech are seeing inflows.
Stock ownership is broadening out, with confidence growing outside of the well-known large cap stocks. 

Shenzhen Mindray Bio-Medical Electronics (300760 CH) ,  Xian Longi Silicon Materials (601012 CH)  and Lepu Medical Technology A (300003 CH) are seeing investment levels rise among EM investors.


LONGi Green Energy Technology (601012 CH)

Shenzhen Mindray Bio-Medical Electronics (300760 CH)

China A-Share Boom. Overtakes Russia in GEM Portfolios. Health/Tech/Industrials Lead.